References
- Cynamon MH, Klemens SP, Sharpe CA, Chase S. Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999; 43: 1189–1191.
- Goldstein EJ, Citron DM, Merriam CV. Linezolid activity compared to those of selected macrolides and other agents against aerobic and anaerobic pathogens isolated from soft tis-sue bite infections in humans. Antimicrob Agents Chemother 1999; 43: 1469–1474.
- Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important gram-posi-tive bacterial pathogens including vancomycin-resistant entero-cocci. Antimicrob Agents Chemother 1999; 43: 2059–2062.
- Pe1ton SI, Figueira M, Albut R, Stalker D. Efficacy of linezolid in experimental otitis media. Antimicrob Agents Chemother 2000; 44: 654–657.
- Rybak MJ, Cappelletty DM, Moldovan T, Aeschlimann JR, Kaatz GW. Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylo-cocci, Enterococcus faecalis, and Enterococcus faecium. Antimicrob Agents Chemother 1998; 42: 721–724.
- Schulin T, Thauvin-Eliopoulos C, Moellering RC Jr, Eliopoulos GM. Activities of the oxazolidinones linezolid and eperezolid in experimental intra-abdominal abscess due to Enterococcus faecalis or vancomycin-resistant Enterococcus faecium. Antimicrob Agents Chemother 1999; 43: 2873–2876.
- Wise R, Andrews JM, Boswell FJ, Ashby JP. The in-vitro activity of linezolid (U-100766) and tentative breakpoints. J Antimicrob Chemother 1998; 42: 721–728.
- Zurenko GE, Yagi BH, Schaadt RD, et al. In vitro activ-ities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839–845.
- Hof H, Nichterlein T, Kretschmar M. Management of listeriosis. Clin Microbiol Rev 1997; 10: 345–357.
- Jones EM, MacGowan AP. Antimicrobial chemothera-py of human infection due to Listeria monocytogenes. Eur J Clin Microbiol Inf Dis 1995; 14: 165–175.
- Bauer J, Hof H, Nichterlein T, Wuenscher M. Comparative activities of macrolide derivatives on murine liste-riosis. Zbl Bakt 1993; 278: 112–119.
- Nichterlein T, Kretschmar M, Budeanu C, Bauer J, Linss W, Hof H. Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob Agents Chemother 1994; 38: 1501–1506.
- Portnoy DA. Innate immunity to a facultative intracellu-lar pathogen. Curr Opinion Immunol 1992: 4: 20–24.
- Schltiter D, Oprisiu SB, Chahoud S, et al. Systemic immunization induces protective CD4+ and CD8+ T cell medi-ated immune responses in murine Listeria monocytogenes meningoencephalitis. Eur J Immunol 1995; 25: 2384–2391.
- Peterson, LR, Shanholtzer CJ. Tests for bactericidal effects of antimicrobial agents: technical performances and clinical relevance. Clin Microbiol Rev 1992; 5: 420–432.
- Nichterlein T, Kretschmar M, Hof H. The ketolide antibiotic HMR 3647 is a candidate substance for the treat-ment of systemic and intracerebral infections with Listeria monocytogenes. Zbl Bald 1999; 289: 155–164.